BRAF V600E mutation in papillary thyroid cancer is correlated with adverse clinicopathological features but not with iodine exposure

Ozcelik, Serhat; Bircan, Rifat; Sarikaya, Sukran; Gul, Aylin; Aydin, Busra; Ozcelik, Melike; Celik, Mehmet; Dayan, Akin; Tutuncu, Yasemin; Cengiz, Hasret; Karadayi, Nimet; Gozu, HÜLYA

doi:10.5603/ep.a2019.0025

BRAF V600E mutation in papillary thyroid cancer is correlated with adverse clinicopathological features but not with iodine exposure

Ozcelik S., Bircan R., Sarikaya S., Gul A. E., Aydin B., Ozcelik M., ...Daha Fazla

ENDOKRYNOLOGIA POLSKA, cilt.70, ss.401-408, 2019 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 70
Basım Tarihi: 2019
Doi Numarası: 10.5603/ep.a2019.0025
Dergi Adı: ENDOKRYNOLOGIA POLSKA
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.401-408
Anahtar Kelimeler: papillary thyroid cancer, BRAF V600E, iodine, BRAF V600E MUTATION, BRAF(V600E) MUTATION, PREVALENCE, CARCINOMA, ASSOCIATION, RECURRENCE, GENE
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Marmara Üniversitesi Adresli: Evet

Özet

Introduction: BRAF(V600E) activating mutation is the most frequent genetic abnormality in the pathogenesis of papillary thyroid carcinoma. We aimed to evaluate the association between BRAF(V600E )mutation and well-established prognostic clinicopathological characteristics as well as iodine exposure.